Form 4: Cryoport Director Exercises Options, Sells Shares

Cryoport Director Robert J. Hariri exercised stock options and subsequently sold a portion of the acquired shares to cover costs.

Summary

• Director Robert J. Hariri exercised 50,000 stock options at an exercise price of $2.66 per share on September 11, 2025.
• Concurrently, Hariri sold 25,000 shares of Cryoport, Inc. common stock at a weighted average price of $9.7095 per share.
• The proceeds from the sale of common stock were utilized to cover the exercise price and withholding taxes associated with the option exercise.
• Following these transactions, Hariri's direct beneficial ownership of common stock in Cryoport, Inc. stands at 51,275 shares.
• The transactions were conducted pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction where a director exercised stock options and sold a portion of the shares to cover the exercise cost and taxes. While the sale reduces direct insider holdings, the exercise itself indicates the options were significantly in-the-money, reflecting past stock price appreciation. The transaction was pre-planned under a 10b5-1 plan, which is a neutral factor for sentiment.

Positives

• Director Hariri realized value from his equity compensation by exercising stock options, demonstrating the options were significantly in-the-money.
• The exercise price of $2.66 is substantially lower than the sale price of $9.7095, indicating a favorable gain on the options.
• The transaction was executed under a Rule 10b5-1(c) plan, which provides an affirmative defense against insider trading allegations and suggests a pre-planned, compliant approach to equity management.

Negatives

• Director Hariri reduced his direct beneficial ownership of common stock by 25,000 shares, from an implied 76,275 shares (after option exercise) to 51,275 shares.
• The sale of shares, even for tax and exercise cost purposes, represents a decrease in direct insider holdings.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance, strategic direction, or financial estimates. It solely reports past insider transactions.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, specifically an option exercise and subsequent 'sell-to-cover' transaction. Such transactions are common for executives and directors managing their equity compensation and tax obligations across various industries. It does not provide insights into broader industry trends or competitive positioning for Cryoport, Inc.

Comparison to Industry Standards

• The reported transaction, involving the exercise of stock options and a 'sell-to-cover' sale, is a standard practice for managing equity compensation among executives and directors in publicly traded companies across all sectors.
• There are no specific company or project results within this filing to compare against industry benchmarks or specific comparable companies like BioLife Solutions (BLFS) or other cold chain logistics providers, as it is purely a transactional report.

Stakeholder Impact

• Shareholders: The reduction in direct insider ownership by 25,000 shares might be viewed neutrally or slightly negatively, though it is a common 'sell-to-cover' transaction and does not necessarily indicate a change in the director's long-term view of the company.
• Employees: No direct impact on employees is indicated by this transactional filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this transactional filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and a subsequent sale of shares to cover the exercise price and taxes. Such 'sell-to-cover' transactions are common and typically do not signal a change in the company's fundamental outlook or the insider's long-term conviction. While there's a slight reduction in direct insider ownership, it's within the scope of normal equity compensation management. Therefore, the filing itself does not provide sufficient new information to warrant a change from a 'hold' recommendation, assuming no other significant news or fundamental changes for Cryoport, Inc.

Keywords

Cryoport, CYRX, Insider Trading, Form 4, Stock Options, Director, Share Sale, Equity Compensation, Robert J. Hariri, Rule 10b5-1